EPISODE · Mar 5, 2026 · 10 MIN
EP 119.新药上市的指挥棒，药企全生命周期 KPI 实战指南
from MedVerse医路人
🚀 在新药研发成本动辄十亿美元的今天，产品获批仅仅是拿到入场券，真正的较量在于上市准备期。本期播客将深度解码辉瑞、诺和诺德、罗氏等顶尖药企的新品上市 KPI 秘诀。我们将跳出传统的唯销量论，探讨如何利用平衡计分卡（BSC）与数字化监控平台，打造一套从临床研发、市场准入到商业变现的全周期、动态化指挥棒。💡 本期播客核心看点： 三大赛道的定制化标尺 战略解码与工具赋能 本地化与动态防御机制 2026 后疫情时代新风向关于节目《MedVerse 医路人》是一档聚焦医药行业职业发展、市场与学术推广、以及行业趋势观察的播客。我们希望通过行业解析、案例分享与对话讨论，帮医药人看清职场成长的底层逻辑，找到更清晰的发展路径。找到我们公众号：MedVerse Pro小红书：达利Dali收听渠道：小宇宙、苹果Podcast、QQ音乐*扣子空间前往小宇宙评论区与主播互动
Embed this episode
Ready to play
EP 119.新药上市的指挥棒，药企全生命周期 KPI 实战指南
0:00
10:05
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MedVerse医路人?
This episode is 10 minutes long.
When was this MedVerse医路人 episode published?
This episode was published on March 5, 2026.
Can I download this MedVerse医路人 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!